Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder: A Randomized Clinical Trial

Adriana Feder, MD; Michael K. Parides, PhD; James W. Murrough, MD; Andrew M. Perez, MD; Julia E. Morgan, BA; Shireen Saxena, MScPh; Katherine Kirkwood, MS; Marije aan het Rot, PhD; Kyle A. B. Lapidus, MD, PhD; Le-Ben Wan, MD, PhD; Dan Iosifescu, MD; Dennis S. Charney, MD

IMPORTANCE Few pharmacotherapies have demonstrated sufficient efficacy in the treatment of posttraumatic stress disorder (PTSD), a chronic and disabling condition.

OBJECTIVE To test the efficacy and safety of a single intravenous subanesthetic dose of ketamine for the treatment of PTSD and associated depressive symptoms in patients with chronic PTSD.

DESIGN, SETTING, AND PARTICIPANTS Proof-of-concept, randomized, double-blind, crossover trial comparing ketamine with an active placebo control, midazolam, conducted at a single site (Icahn School of Medicine at Mount Sinai, New York, New York). Forty-one patients with chronic PTSD related to a range of trauma exposures were recruited via advertisements.

INTERVENTIONS Intravenous infusion of ketamine hydrochloride (0.5 mg/kg) and midazolam (0.045 mg/kg).

MAIN OUTCOMES AND MEASURES The primary outcome measure was change in PTSD symptom severity, measured using the Impact of Event Scale–Revised. Secondary outcome measures included the Montgomery-Asberg Depression Rating Scale, the Clinical Global Impressions–Severity and–Improvement scales, and adverse effect measures, including the Clinician-Administered Dissociative States Scale, the Brief Psychiatric Rating Scale, and the Young Mania Rating Scale.

RESULTS Ketamine infusion was associated with significant and rapid reduction in PTSD symptom severity, compared with midazolam, when assessed 24 hours after infusion (mean difference in Impact of Event Scale–Revised score, 12.7 [95% CI, 2.5-22.8]; P = .02). Greater reduction of PTSD symptoms following treatment with ketamine was evident in both crossover and first-period analyses, and remained significant after adjusting for baseline and 24-hour depressive symptom severity. Ketamine was also associated with reduction in comorbid depressive symptoms and with improvement in overall clinical presentation. Ketamine was generally well tolerated without clinically significant persistent dissociative symptoms.

CONCLUSIONS AND RELEVANCE This study provides the first evidence for rapid reduction in symptom severity following ketamine infusion in patients with chronic PTSD. If replicated, these findings may lead to novel approaches to the pharmacologic treatment of patients with this disabling condition.

TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00749203

Published online April 16, 2014.

Copyright 2014 American Medical Association. All rights reserved.
ostraumatic stress disorder (PTSD) is a chronic and disabling condition arising after exposure to a severe traumatic event, characterized by persistent reexperiencing, avoidance, and hyperarousal symptoms. In the general population, prevalence has been estimated at 7.8%, with higher rates in trauma-exposed populations, particularly among survivors of interpersonal violence. To date, few pharmacotherapies have demonstrated sufficient efficacy in PTSD; selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and other medications are associated with significant levels of nonresponse and persistent residual symptoms, even in responders.

Accumulating evidence for the role of glutamate, the most widely distributed excitatory neurotransmitter, in mediating stress responsivity, the formation of traumatic memories, and the pathophysiology of PTSD, suggests a potential benefit for novel pharmacotherapeutic interventions for this disorder. Recently, intravenous (IV) ketamine, an antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor, has emerged as an effective, rapidly acting intervention for patients with treatment-resistant depression when administered at subanesthetic doses of 0.5 mg/kg. Ketamine is used for anesthesia at doses of 2 mg/kg or higher and for analgesia at subanesthetic doses. It is considered particularly safe because, unlike other anesthetics, it reliably preserves breathing reflexes. Symptomimetic effects include moderate increases in blood pressure, heart rate, cardiac output, and oxygen consumption. Acute psychological adverse effects can include perceptual disturbance, dissociative symptoms, and short-term cognitive impairment.

Few previous studies have examined the effects of ketamine in trauma-exposed individuals, and results from these studies have been mixed. A retrospective study of peritraumatic esketamine medication for patients who had been in accidents reported increased dissociative and acute stress disorder symptoms among these patients, assessed retrospectively 1 year after injury, as well as higher PTSD symptom levels, compared with those who received racemic ketamine or opioids. In a second, prospective naturalistic study of patients who had been in accidents, the patients who received racemic ketamine scored significantly higher than those treated with opioid or nonopioid analgesics on dissociative and acute stress disorder symptoms, within 3 days after admission to the hospital. In contrast, a medical record review of a larger sample of burned servicemembers found a significantly lower prevalence of PTSD among patients who received ketamine during posttrauma surgical procedures than among those who did not (26.89% vs 46.42%; P = .04). Furthermore, in secondary analyses from ketamine clinical trials in mood disorders, patients with PTSD or a history of trauma did not exhibit clinically significant increases in psychotic, dissociative, or anxiety symptoms after a single ketamine infusion. In a recently published case report, IV ketamine administered with propofol was associated with rapid and marked symptom improvement in a veteran with treatment-resistant PTSD.

To our knowledge, no randomized clinical trial examining the effects of ketamine in patients with chronic PTSD has been previously conducted. We conducted a proof-of-concept, randomized, double-blind crossover study to test the effect of a single IV subanesthetic dose of ketamine in patients with chronic PTSD compared with IV administration of the benzodiazepine midazolam, the active placebo control condition. We hypothesized that ketamine would be associated with significantly greater reduction in core PTSD symptom levels 24 hours after a single IV infusion. We further hypothesized that ketamine would have a rapid antidepressant effect in patients with PTSD.

**Methods**

Patients with chronic PTSD were enrolled at the Icahn School of Medicine at Mount Sinai, New York, New York, between May 2009 and December 2012. Eligible participants were between 18 and 55 years of age, had a primary diagnosis of PTSD assessed with the Structured Clinical Interview for *DSM-IV-TR* Axis I Disorders—Patient Version and a score of at least 50 on the Clinician-Administered PTSD Scale (CAPS). Exclusion criteria included a lifetime history of psychotic or bipolar disorder, current bulimia or anorexia nervosa, alcohol abuse or dependence in the previous 3 months, serious unstable medical illness or sleep apnea, active suicidal or homicidal ideation on presentation, or current use of any psychotropic medications. All patients underwent a physical examination and laboratory screening, including routine hematologic, biochemical, and urine toxicology testing, as well as undergoing electrocardiography to rule out unstable medical illness and active substance use. To receive the second IV infusion, a CAPS score of at least 50 was required prior to the second infusion. The institutional review board at Mount Sinai approved the study, and written informed consent was obtained from all study participants. Participants were compensated for their time.

**Procedures**

Study participants were free of concomitant psychotropic medications for 2 weeks prior to randomization and for the duration of the study. For each procedure day, patients were assigned to receive a single IV infusion of ketamine hydrochloride (0.5 mg/kg) or midazolam (0.045 mg/kg), administered over 40 minutes. The order of infusions (ketamine then midazolam or midazolam then ketamine) was randomly assigned, and administrations were 2 weeks apart. Midazolam was chosen as the active placebo control because its pharmacokinetic parameters and nonspecific behavioral effects are similar to those of ketamine. Only the research pharmacy was aware of drug identity, and all study personnel, including investigators, anesthesiologists, raters, patients, and data analysts, were blinded to randomization order.

Following admission to Mount Sinai’s Clinical Research Unit and an overnight fast, an indwelling catheter was placed in the antecubital vein of the nondominant arm. Monitoring of pulse and blood pressure, pulse oximetry, and electrocardiographic monitoring were instituted (see Murrough et al. for details). Ratings were administered by a trained rater during infusions and 40, 120, and 240 minutes after infusion. A
different trained rater, blinded to the ratings conducted during and after infusion on infusion days, administered ratings at preinfusion baseline and 24 hours (day 1) after infusion (before patients were discharged from the hospital), 48 hours (day 2) after infusion, 72 hours (day 3) after infusion, and 7 days (day 7) after infusion. Ratings were also administered 10 and 13 days after infusion, although data analyses focused on the first week after infusion owing to the expected duration of ketamine action. Patients were instructed to abstain from taking psychotropic medications and from using alcohol or substances of abuse for the duration of the trial. As already described, patients who scored 50 or higher on the CAPS 2 weeks after the first infusion received an infusion of the second study drug. Patients whose symptoms remained significantly improved 2 weeks after infusion (indicated by a CAPS score of <50 at 2 weeks) were considered to have completed the study after 1 infusion.

Outcomes
The primary outcome was PTSD symptom severity 24 hours after infusion, assessed with the Impact of Event Scale-Revised (IES-R). Twenty-four hours after infusion was selected as the primary end point because acute sedating and other side effects were expected to have resolved, while potential symptom improvement was expected to persist at 24 hours. Secondary outcome measures included the Montgomery-Asberg Depression Rating Scale (MADRS), the Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR), and Clinical Global Impression–Severity (CGI-S) and –Improvement (CGI-I) scales administered by a study clinician 24 hours, 48 hours, 72 hours, and 7 days after infusion. The IES-R was also administered 48 hours, 72 hours, and 7 days after infusion. The CAPS was administered at baseline and 7 days after infusion.

General side effects and possible dissociative, psychotomimetic, and manic symptoms were measured with the Patient-Rated Inventory of Side Effects, the Clinician-Administered Dissociative States Scale, the 4-item positive symptoms subscale, and item 1 (elevated mood) of the Young Mania Rating Scale. The Patient-Rated Inventory of Side Effects is a 9-item self-report scale that inquires about side effects in 8 organ systems and other general side effects.

Statistical Analysis
The ability of ketamine to reduce PTSD symptoms was assessed in a proof-of-concept, randomized, double-blind, crossover trial. A total of 41 patients were enrolled, with order of treatment determined by randomization. The primary analysis adhered to a modified intention-to-treat principle, including all 29 patients with outcome assessments from both periods. A mixed-model approach was used to test effects of treatment, period, and carryover. An additional intention-to-treat analysis of covariance, adjusting for baseline IES-R score, was conducted with all 41 patients using only first-period data. All statistical tests were 2-sided .05-level tests. Secondary analyses of additional end points followed the same analytic approach as for the primary end point. No adjustment for multiple tests was made; all P values are reported at their nominal level. The primary interest was on changes in symptom outcomes observed during the first week, given the hypothesized duration of the effects of ketamine. A planned sample size of 40 patients randomly assigned to treatment order was estimated to provide 80% power to detect a hypothesized treatment difference in change in IES-R scores of 0.9 SD units 24 hours after infusion.

Secondary analyses also examined the effect of depression on PTSD symptoms and the interaction between treatment and depression. A mixed-model approach was used to examine the effects of treatment, baseline MADRS score, and 24-hour MADRS score using only first-period data. Safety and tolerability were analyzed using descriptive statistics.
**Table 1. Demographic and Clinical Characteristics of Study Participants**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Ketamine a (n = 22)</th>
<th>Midazolam b (n = 19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>36.4 (10.8)</td>
<td>35.7 (10.0)</td>
</tr>
<tr>
<td>Female, sex, No. (%)</td>
<td>13 (59.1)</td>
<td>6 (31.6)</td>
</tr>
<tr>
<td>Race, No. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>11 (50.0)</td>
<td>12 (63.2)</td>
</tr>
<tr>
<td>White</td>
<td>5 (22.7)</td>
<td>2 (10.5)</td>
</tr>
<tr>
<td>Other</td>
<td>6 (27.3)</td>
<td>5 (26.3)</td>
</tr>
<tr>
<td>Hispanic ethnicity, No. (%)</td>
<td>5 (22.7)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Education, No. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤High school</td>
<td>1 (4.8)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>High school graduate</td>
<td>3 (14.3)</td>
<td>3 (15.8)</td>
</tr>
<tr>
<td>Some college</td>
<td>12 (57.1)</td>
<td>14 (73.7)</td>
</tr>
<tr>
<td>≥4 Years of college</td>
<td>5 (23.8)</td>
<td>2 (10.5)</td>
</tr>
<tr>
<td>Unemployed, No. (%)</td>
<td>11 (50.0)</td>
<td>14 (73.7)</td>
</tr>
<tr>
<td>Married or cohabiting, No. (%)</td>
<td>5 (22.7)</td>
<td>3 (15.8)</td>
</tr>
<tr>
<td>Primary trauma, No. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sexual assault or molestation</td>
<td>9 (40.9)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Physical assault or abuse</td>
<td>4 (18.2)</td>
<td>7 (36.8)</td>
</tr>
<tr>
<td>Accident or fire</td>
<td>1 (4.5)</td>
<td>3 (15.8)</td>
</tr>
<tr>
<td>Combat exposure</td>
<td>2 (9.1)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Witnessed violent assault or death</td>
<td>4 (18.2)</td>
<td>5 (26.3)</td>
</tr>
<tr>
<td>Witnessed 9/11 terrorist attacks</td>
<td>2 (9.1)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Duration of PTSD, mean (SD), y</td>
<td>14.2 (12.3)</td>
<td>11.9 (14.0)</td>
</tr>
<tr>
<td>History of treatment with psychotropic medication, No. (%)</td>
<td>11 (50.0)</td>
<td>8 (42.1)</td>
</tr>
<tr>
<td>CAPS score (past month), mean (SD)</td>
<td>82.5 (14.1)</td>
<td>77.1 (11.8)</td>
</tr>
<tr>
<td>QIDS-SR score, mean (SD)</td>
<td>12.4 (5.2)</td>
<td>11.3 (5.6)c</td>
</tr>
</tbody>
</table>

**Abbreviations:** CAPS, Clinician-Administered PTSD Scale; PTSD, posttraumatic stress disorder; QIDS-SR, Quick Inventory of Depressive Symptomatology. Self-Report.  

a Patients randomly assigned to receive ketamine first.  
b Patients randomly assigned to receive midazolam first.  
c Missing data for 1 patient who was randomly assigned to receive ketamine first (n = 21).  
d Missing data for 4 patients who were randomly assigned to receive midazolam first (n = 15).

**Results**

**Study Participants**

Of 57 potential participants who completed informed consent procedures, 41 met eligibility criteria and were randomly assigned to receive ketamine or midazolam during the first infusion. All 41 patients received study medication and completed 24-hour ratings; 29 of them completed both infusions and ratings following each infusion (Figure 1). Of the remaining 12 participants, 6 (all of whom had been randomly assigned to receive ketamine first) completed the study at 2 weeks, following only their first infusion and ratings, because their CAPS scores were less than 50 at 2 weeks, precluding the second infusion. Two additional participants also had a CAPS score of less than 50 at 2 weeks, one who received ketamine first and the other who received midazolam first, but they both received their second infusion a week later (eTable 1 in Supplement).

**Demographic and Clinical Characteristics**

Table 1 summarizes the demographic and clinical characteristics of patients randomly assigned to receive ketamine or midazolam. All patients had chronic PTSD, in most cases persisting for several years with moderate to severe symptoms (Table 1). Fewer than 50% of the participants had received psychotropic medication in the past, generally 1 or 2 antidepressants with partial or no response (although occasionally with good response), and few had received additional medications such as a benzodiazepine, a sedative-hypnotic agent, prazosin hydrochloride, or an atypical antipsychotic agent. Prior to beginning study procedures, only 2 patients required a psychotropic medication taper, one from topiramate and the other from amphetamine/dextroamphetamine mixed salts.

**Primary Outcome**

In the crossover analysis, total IES-R scores 24 hours after infusion were significantly improved with ketamine compared with midazolam (mean difference, 12.7 [95% CI, 2.5-22.8]; P = .02). There was no evidence of any period or residual effects for the crossover. In addition, symptoms in 7 patients randomly assigned to ketamine first remained significantly reduced after infusion, compared with only 1 patient randomly assigned to midazolam first. Analysis of IES-R scores at 24 hours based on the first period only, including all 41 randomly assigned patients, agreed closely (mean difference, 8.6 [95% CI, 0.94-16.2]; P = .03). Neither a diagnosis of major depressive disorder at screening nor the MADRS score at preinfusion baseline had a significant effect on the change in IES-R score at 24 hours.

**Secondary Outcomes**

**Additional 24-Hour Outcomes and CAPS Scores at 7 days**

Ketamine had a similar effect on the 3 PTSD symptom clusters, measured by the IES-R subscales (Table 2 and Figure 2). In crossover analyses with 29 patients, the CGI-S and CGI-I scores at 24 hours were also significantly better following ketamine (Table 2). Analysis of CGI-S and CGI-I scores at 24 hours based on the first period only, including all 41 randomly assigned patients, supported the findings from crossover analyses (Table 2). Crossover analyses (29 patients) of MADRS and QIDS-SR scores at 24 hours did not yield any significant effect of ketamine treatment over the control condition. The mean CAPS score 7 days after infusion did not differ significantly by treatment (mean difference between ketamine and midazolam, 8.7 [95% CI, −4.8 to 22.2]; P = .20) (eTables 2-4 in Supplement). Results did not change after analyses were conducted without the 2 patients who received their second infusion 1 week later.

**Comorbid Depressive Symptoms**

In additional first-period analyses with all 41 patients, treatment assignment (β = 6.5, P = .0496), MADRS score 24 hours...
Table 2. Clinical Improvement at 24 Hours in IES-R Score and Secondary Outcomes: Crossover and First Infusion Results

<table>
<thead>
<tr>
<th>Measure</th>
<th>Crossover (n = 29)</th>
<th>First Infusion (n = 41)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean Difference</td>
<td>P Value</td>
</tr>
<tr>
<td></td>
<td>(95% CI)</td>
<td></td>
</tr>
<tr>
<td>IES-R total scorea</td>
<td>12.7 (2.5–22.8)</td>
<td>.02</td>
</tr>
<tr>
<td>Intrusion</td>
<td>4.0 (−0.3 to 8.3)</td>
<td>.07</td>
</tr>
<tr>
<td>Avoidance</td>
<td>4.8 (0.2–9.3)</td>
<td>.04</td>
</tr>
<tr>
<td>Hyperarousal</td>
<td>3.9 (0.6–7.2)</td>
<td>.02</td>
</tr>
<tr>
<td>CGI-S scale score</td>
<td>1.0 (0.1–1.9)</td>
<td>.03</td>
</tr>
<tr>
<td>CGI-I scale score</td>
<td>1.2 (0.3–1.9)</td>
<td>.003</td>
</tr>
<tr>
<td>QIDS-SR score</td>
<td>0.2 (−3.9 to 4.3)</td>
<td>.93</td>
</tr>
<tr>
<td>MADRS score</td>
<td>3.7 (−7.5 to 14.9)</td>
<td>.51</td>
</tr>
</tbody>
</table>


a Primary outcome measure.
after infusion ($\beta = 0.9, P = .0004$), and baseline IES-R score ($\beta = 0.2, P = .04$) were shown to have significant effects on the IES-R score 24 hours after infusion, with ketamine showing significantly better improvement than midazolam. Baseline MADRS score and the interaction between 24-hour MADRS score and treatment were not significant predictors of IES-R score 24 hours after infusion.

**Durability of Drug Effect**

Generalized linear mixed modeling analyses of the first period only, including all 41 randomized patients, evaluated IES-R, MADRS, and QIDS-SR scores 24, 48, and 72 hours and 7 days after infusion as a function of treatment, time, and treatment-by-time interaction (Figure 2). Analyses demonstrated a significant effect of treatment on the IES-R score (differences of least squares means estimate, $-8.32 \ [P = .046]$) and the QIDS-SR score ($-2.73 \ [P = .050]$) and a significant effect of time on the IES-R, MADRS, and QIDS-SR scores. The effect of treatment on the MADRS score approached significance ($-3.99 \ [P = .052]$). There were no significant treatment-by-time interactions.

**Adverse Events**

Dissociative symptoms after treatment with ketamine were short-lived, peaking at 40 minutes, and had resolved by the next assessment 120 minutes from start of infusion (Figure 3). No emergence of significant psychotic or manic symptoms was observed (Figure 3). One participant dropped out after his second infusion (ketamine), stating that he felt uncomfortable during the infusion owing to likely dissociative effects. Infusion was discontinued after 15 minutes for another patient who received a higher dose of ketamine in error. Three patients required acute treatment with $\beta$-blockers during ketamine infusion because of blood pressure elevation (systolic blood pressure $>180$ mm Hg and/or diastolic blood pressure $>100$ mm Hg). With the Patient-Rated Inventory of Side Effects, the most frequently reported general adverse effects of ketamine (vs midazolam) in the first 24 hours following infusion included blurred vision (36% vs 19%), dry mouth (21% vs 16%), restlessness (23% vs 10%), fatigue (21% vs 23%), nausea/vomiting (21% vs 3%), poor coordination (15% vs 3%), and headache (13% vs 13%) (eTable 5 in Supplement).

**Discussion**

A single dose of ketamine, compared with a psychoactive placebo medication, was associated with rapid reduction in core PTSD symptoms in patients with chronic PTSD, and benefit frequently was maintained beyond 24 hours. Symptoms remained significantly reduced at 2 weeks in 7 patients who responded to ketamine compared with 1 patient who responded to midazolam, as indicated by a CAPS score of less than 50. These data provide the first randomized, controlled evidence that NMDA receptor modulation can lead to the rapid clinical reduction of core PTSD symptoms in patients with chronic PTSD. Greater reduction in PTSD symptom severity following ketamine infusion compared with midazolam infusion remained significant even after adjusting for baseline and 24-hour depressive symptom severity. Although the reductions in PTSD and depressive symptoms might be related, this finding suggests an effect of ketamine on PTSD symptom levels over and above the effects on depressive symptoms. Ketamine was also associated with the reduction in comorbid depressive symptoms, possibly broadening the therapeutic use of NMDA receptor modulation for the treatment of depressive symptoms in PTSD patients, who frequently have comorbid major depressive disorder. Patients also showed improvement in global clinical ratings following ketamine infusion. Although reduction in
depressive symptoms in patients with PTSD who received ketamine was less pronounced than that reported in studies of patients with treatment-resistant major depressive disorder, this sample was not selected for the presence of major depressive disorder or for depressive symptom severity.

We also demonstrated that a single dose of IV ketamine is a safe and generally well-tolerated intervention for patients with chronic PTSD; ketamine was associated with only transient dissociative symptoms, without significant emergence of psychotic or manic symptoms. These initial findings also allay concerns about possible worsening of PTSD symptoms following ketamine administration, at least in patients with chronic PTSD, including any sustained induction or worsening of dissociative symptoms. Our findings necessitate replication and further study.

The strengths of our study include the enrollment of patients with moderate to severe PTSD symptom levels, the use of the active placebo control midazolam, which strengthened the blind (compared with saline solution) because midazolam can also induce transient psychoactive effects, and the shielding of the primary outcome rater from adverse effects occurring during the day of infusion. Of note, ketamine demonstrated a superior effect to that of midazolam, despite the fact that midazolam may have a potential acute benefit in a study of patients with chronic PTSD, because it is also a well-known anxiolytic. Although practice guidelines recommend against the use of benzodiazepines for the treatment of PTSD, only 2 randomized clinical trials examining benzodiazepine efficacy in PTSD treatment have been published. Benzodiazepines, through their actions on the γ-aminobutyric acid A receptor complex, have demonstrated anxiolytic, sedative, hypnotic, muscle relaxant, and amnestic effects in patients with anxiety disorders and other conditions.

The biological mechanisms underlying the effects of ketamine, a glutamate NMDA receptor antagonist, in patients with PTSD are unknown. The role of glutamate in memory formation, including trauma-related memories, and in the pathophysiology of PTSD has recently received increased attention. Although acute stress enhances glutamate transmission in the prefrontal cortex, chronic stress disrupts it. Animal studies have demonstrated reductions in synaptic density and complexity in the prefrontal cortex and hippocampus secondary to chronic stress. More recently, ketamine has been shown to rapidly increase the number and function of synaptic connections in the prefrontal cortex, rapidly reversing behavioral and neuronal changes resulting from chronic stress in rats, partially through activation of the mammalian target of rapamycin signaling pathway and stimulation of brain-derived neurotrophic factor signaling.

The limitations of our study include the fact that several patients did not receive a second infusion, but in half of these patients, this second infusion was prevented per protocol because of sustained reduction in PTSD symptom levels 2 weeks after ketamine infusion. Ketamine was associated with transient but higher rates of dissociative symptoms than midazolam, likely affecting the blind. The present study also does not address the important question of the safety or efficacy of ketamine in combination with other psychotropic medications in PTSD. Ketamine is associated with very few drug-drug interactions, and no contraindications exist to its combination with antidepressants, benzodiazepines, or other psychotropic medications.

Conclusions
Our results provide the first evidence that a single dose of IV ketamine was associated with rapid reduction of core PTSD symptoms and reduction in comorbid depressive symptoms in patients with chronic PTSD and that it was generally well tolerated without clinically significant persistent dissociative symptoms. Future studies are needed for replication, and they should examine the efficacy and safety of ketamine administration beyond a single infusion for patients with chronic PTSD, explore the use of ketamine anesthesia to prevent the emergence of PTSD symptoms in surgical patients with a history of trauma, investigate the mechanisms of ketamine action, and identify pretreatment predictors of response to this intervention.
and Feder and Mount Sinai could benefit financially. No other disclosures are reported.

Funding/Support: This study was funded by grant W81XWH-08-1-0602 from the Department of the Army–US Army Medical Research Acquisition Activity (Dr Charney, principal investigator).

Role of the Sponsor: The funding agency had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Solara Calderon, BA, provided assistance with participant recruitment and ratings. Jazmin Moral, LCSW, provided assistance with clinical assessments and ratings. Jess Brailer, MD, an anesthesiologist, provided assistance with study procedures. Jess Brailer, MD, an anesthesiologist, provided assistance with study procedures. They all received financial compensation.

REFERENCES


